U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent
Dec 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.
HIGHLIGHTS
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order
* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating |
* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating |
* BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3 |
* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 |
* Emergent Biosolutions EBS.N: H.C. Wainwright initiates coverage with buy rating; PT $15 |
* Exelixis Inc EXEL.O: RBC raises target price to $38 from $34 |
* Insulet Corp PODD.O: BTIG raises target price to $300 from $270 |
* Metavia Inc MTVA.O: H.C. Wainwright initiates coverage with buy rating; PT $12 |
* Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Related Articles
The Ultimate AI Investment Guide:Opportunities, Risks, and Strategies for the Next Generation of Technology Markets
TradingKey - OpenAI’s recent multi-billion-dollar partnerships—with Nvidia, AMD, and Broadcom—have flooded headlines and lifted markets, but they’ve also sparked a new round of debate: Is Sam Altman steering us toward a runaway tech bubble
TSMC Q3 Earnings Preview: Record Revenue Is a Lock, but an Upgraded Outlook Could Be the Real Catalyst
TradingKey - Global semiconductor foundry leader Taiwan Semiconductor Manufacturing Company (TSMC, TSM) will report its Q3 2025 earnings on Thursday, October 16, before U.S. markets open. With record-breaking revenue already confirmed by monthly reports, analysts expect record profits and
What Is the Debasement Trade? Markets Have Picked Three Winners and One Loser
TradingKey - Since October, as the U.S. dollar, yen, and euro weaken, while gold, silver, and Bitcoin surge to new highs, Wall Street has embraced a powerful new investment narrative: the “Debasement Trade.” This term captures the extraordinary shift of capital from traditional currencies and
UK August GDP: Economy & Assets—Set to Collapse?
TradingKey - The UK is scheduled to release its August GDP figures on 16 October, with the market widely anticipating a 0.1% month-on-month increase in real GDP (Figure 1). If this expectation is fulfilled, it will represent the UK economy’s third consecutive month of recovery, following two straigh
U.S. Banks Q3 Earnings Preview: Big 5 Banks See Double-Digit EPS Growth, Investment Banking Hits 4-Year High
TradingKey - The 2025 U.S. earnings season kicks off this week with results from major banks. Amid elevated investor sentiment and the Trump administration pushing for deregulation, analysts expect another strong quarter for the banking sector — driven by booming trading activity and a resurgence
